Folks, the FDA’s decision on the pharmaceutical agents listed below is expected to cause volatility, particularly in the shares of the following companies. AMGN’s anemia Drug for chemotherapty patients is expected to have new guidelines regarding the usage of the drug. Although the FDA’s revision might hamper AMGN’s revenue, the shares have already discounted the news. Therefore, I stand adamantly by my “buy” recommendation on AMGN.

New: Join my personal mailing list for instant trade updates.

Related Posts:

• CROX: Sales growth of 99% should not intimidate anyone of rising 4th quarter inventories!
• Positive breadth for the S&P 500
• AMGN’s shares are factoring in FDA’s upcoming meeting
• INTC- -27% in 11 trading days!

Filed Under Stock Insight and Stock News and Stock Trades |
Subscribe to the Blog | Recieve Blog Updates by Email!

----------------------------------------

Share Your Knowledge »